World ADC London 2020
Celebrating its 10th year, World ADC is returning to London bigger and better than ever. Covering the A to Z of ADCs, World ADC London will continue to curate and distil the field’s latest scientific advances and lessons learned, particularly from the last 12 months. Join the likes of AstraZeneca, Sanofi and Bayer at this definitive forum to maximise the therapeutic index of your ADC pipeline.
In 2020 you will gain an unrivalled learning experience, across 4 packed days with 4 parallel tracks, including a new track on protein engineering and more on clinical, regulatory and manufacturing challenges.
Download the full programme to see how this meeting is your one stop shop for all things ADC.
Here’s a snapshot of the 60+ world-class speaker faculty:
- Thorsten Sperber, Global Head Medical Affairs, Immunomedics
- Daejin Abidoye, Vice Present, Clinical Development, Seattle Genetics
- Bart de Goeij, Assistant Director, Genmab
- Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
- John Babcook, Senior Vice President of Discovery Research, Zymeworks
- Hillary Schuessler, Scientific Leader, GSK
- Jeremy Parker, Senior Principal Scientist – New Modalities & Tissue Targeting, AstraZeneca
- Luc Desoyners, Senior Director of Translational Sciences, CytomX
- Julian Andreev, Senior Staff Scientist & Research Fellow, Regeneron
- Eric Lacoste, Organic Team & Chemistry, Manufacturing, Control & Project Manager, Sanofi
- Gavin Bennett, Director & Project Leader, Bicycle Therapeutics
- Dan Custar, Associate Director, Drug Substance CMC, Mersana
- Thomas Pillow, Senior Scientist, Genentech
- Guy De Roo, Downstream Processing, Synthon
- Daniel Shweizer, Fellow & Project Leader, Novartis
- Hans Georg Lerchen, Chief Scientist, Medicinal Chemistry, Bayer
For the complete world-class speaker faculty and full agenda, download the full event guide.
As Europe’s largest gathering of ADC stakeholders, seize the opportunity to network with 320 drug developers from 160 active ADC organisations as they strive to develop the next generation of clinically impactful ADCs.
